BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, December 16, 2025
Home » Blogs » BioWorld MedTech Perspectives » Be honest, be open, and be upfront about devices

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech

Be honest, be open, and be upfront about devices

May 6, 2011
By Omar Ford

A couple of weeks ago I interviewed PixelOptics' president/CEO Ron Blum, about a technology called emPower, a device that could eventually replace bifocals.

Now there's one thing you need to know about the interview. 

 Blum is one of those people that med-tech journalists just love to talk to. He’s honest, upfront and has a sort of passion about his product that you just don’t see that often. He’s not  regurgitating facts, or bedazzling you with technical terms that can sometimes go straight over your head.

But rather, Blum is a master of his craft. And if  emPower is anything like its CEO, then we’re going to have a lot less people wearing bifocals in the near future - because he is just that convincing.   

And here’s what I think some med-tech companies are missing. They’re missing that one person who is tailor made to get their point across. Companies are missing that person who has the power and the authority to have an honest conversation about the technology and kick out a lot of P.R. jargon that tends to creep up in interviews.

My only problem with the Blum interview is that it couldn’t go longer. But alas deadlines are a harsh reality for daily publications.

My point is this, when companies are trying to get out the message about their products, they should talk a little bit about what the product could mean for the patient. Don’t give numbers or stats, those will most likely be presented in the press release. Instead try to personalize the experience, let the interviewer and the audience know what’s at stake.

Blum, with so much media attention placed on emPower was fully aware of the stakes and was brutally honest with Medical Device Daily about what that meant for him and the company.

He told me, “When you have this kind of attention on a [global scale], which is at least in our industry unprecedented, it's tremendous pressure on a company like PixelOptics to make sure its product lives up to the promise that we deliver what it is we say we're going to deliver."

If only more companies could open up like this.

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 15, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 16, 2025.
  • Neutrophils in the bloodstream

    Neutrophils put the brakes on fat loss

    BioWorld Science
    Fat tissue balances energy by storing lipids during times of abundance and mobilizing them when needed, yet sustained metabolic stress demands mechanisms that...
  • Novo Nordisk semaglutide pill

    CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

    BioWorld
    A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
  • Illustration of siRNA structure

    Peptidream reveals milestone in Alnylam collaboration

    BioWorld Science
    Peptidream Inc. has announced a preclinical development milestone in its collaboration with Alnylam Pharmaceuticals Inc. under their siRNA conjugate discovery...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing